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Natural antibody to sporozoite antigen increasing with transmission intensity and age has been interpreted as supporting the hypothesis that vaccine induced antibody would protect against P. falciparum malaria'.2. Following demonstration that humans could be protected from sporozoite challenge by subunit sporozoite vaccines ((Asn-Ala-Asn-Pro), 5 Asn-Val-Asp-Pro),=R32, with relatively low levels of antibodies against the central repeat region of P. falciparum circumsporozoite protein3'4 second generation vaccines were designed to elicit higher levels of antibody. It may be hypothesized that supra-normal levels of antibodies to sporozoites could protect, even though natural levels are not correlated with the prevalence of parasitemia or time to onset of parasitemia5. Increased T-lymphocyte responses to sporozoite epitopes may protect, since circurnsporozoite protein repeat has a T-lymphocyte epitope'j, and endemic adults have T-lymphocyte responses to an epitope of the circumsporozoite protein repeat7. Efficacy in an endemic population with circumsporozoite repeat (Asn-Ala-Asn-Pro),-tetanus toxoid is unclear'. Immunogenicity and small-scale efficacy trials in malaria naive volunteers identified R32-Toxin A vaccine as suitable for further evaluation'. This vaccine produced high sporozoite antibody levels in non-immune volunteers, was safe, and immunogenic, nearly all vaccinees seroconverting". One of eight volunteers was protected from challenge with laboratory infected mosquitoes, even though titers fell to relatively low levels at the time of challenge.
This endemic field trial was performed because of higher and more sustained antibody levels in response to vaccination with circumsporozoite repeat in a malaria endemic" than in naive3 volunteers and because wild mosquitoes have'* and release13 fewer sporozoites than laboratoryi mosquitoes.
MATERIALS AND METHODS

Study site
The study area, in western Kenya, near Lake Victoria, has been a site of community-based medical research studies' 5 and has been described15-17. The incidence of P. falciparum alone or with P. malariae or P. ovale was 98.1% between 1980 and 1983".
Study design
This was a prospective, placebo-controlled, randomized, paired, double-blinded, active-case-seeking study. P. falciparum malaria incidence has been 90%5, and 89% over 4 months7, therefore a vaccine 50% effective would give an incidence of 45% in the experimental group. In this instance, the number of volunteers needed in each group for significance of 0.05 and power of 0.95 in a 2-tailed test is 29 19. In previous studies in this area the drop-out rate was 15% over 8 months5s7, 1.87% per month or 22.5% per 12 months.
Recruitment, pairing, randomization, anti-malarial clearance, treatment and follow-up
From a censusi7, of five villages near a clinic, an update was made of males between the ages of 18 and 30 years. One hundred and twenty-seven prospective volunteers answered a questionnaire; 110 met criteria; 76 volunteers were enrolled. Volunteers and household family members were offered free medical care during the study and for any potential adverse effect of vaccine or medicines. Inclusion criteria: male, age 18-30 years, in good health, willing to reside in the study area and participate for 12 months, use no bed nets or other malaria prophylaxis during the study, and human immunodeficiency virus-l (HIV) antibody test negative2'. Exclusion criteria: evidence of cardiac, pulmonary, renal or immunologic disease, or antibody to HIV.
Volunteers were asked to pair themselves to sleep in the same house. Paired volunteers were assigned to two groups of similar ages and proportions of hemoglobin AS. Vaccine was randomly assigned. Houses were inspected to ascertain that they were the customary sleeping houses of the community. Reed mats provided uniform ceilings for mosquito resting and collection. Interiors were divided by a wall or curtain into separate sleeping areas. Every 7 days volunteers switched bed positions in houses.
Volunteers were given quinine sulfate 650 mg thrice daily for 3 days and doxcycycline 100 mg twice daily for 7 days, before each of the three vaccinations. After the last vaccination, volunteers were given quinine sulfate 650 mg thrice daily for 3 days and doxycycline twice daily for 28 days to eradicate blood stage and hepatic stage parasites. Clinical workers observed swallowing of medicines. For slide-proven malaria, sulfadoxinepyrimethamine (Fansidar) was prescribed and swallowed in the presence of clinic staff. Chloroquine and amodiaquine were not prescribed. Volunteers were advised to avoid chloroquine and amodioquine, available without prescription, and obtain medicines only from the study clinic.
Follow-up was carried out for 12 months, 6 months after the last vaccination. Each morning, a clinical worker asked if the volunteer felt sick, took the axillary temperature and asked of any medicine taken. Symptoms of malaria were considered to be: fever; chills; sweats; headache; cough; or diarrhea. If the volunteer felt ill with a symptom of malaria, then a blood slide was made. If the volunteer was moderately ill or worse, he was taken to the clinic by the clinical worker for history and physical examination and tests including malaria blood slide read in the clinic. Symptomatic malaria was defined as the presence of one or more of the above symptoms plus a blood slide positive for P. falciparum. Volunteers were given treatment for malaria if they had both a symptom consistent with malaria and a positive blood slide. After each vaccination, volunteers wrote down side-effects.
Vaccine
The experimental vaccine was recombinant (Asn-AlaAsn-Pro, 5 Asn-Val-Asp-Pro),-Leu-Arg (R32LR)*"** covalently linked to purified Pseudomonas aeruginosa toxin A 9. Each dose consisted of R32LR peptide (175 pug), and toxin A (225 pg)" or recombinant hepatitis B vaccine (Energix B, SmithKline Beecham) control. Malaria (Swiss Serum and Vaccine Institute) and hepatitis vaccines were sent separately to Kenya. Vaccines were kept and transported at +4"C, in the dark, until use.
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Vaccine 1996 Volume 14 Number 8 Scheduled blood slides, in duplicate, were made every 7 days23 from 2 weeks before until 52 weeks after the first vaccination and the number of parasites mm ~ 3 was determined. Symptomatic blood slides were examined at the clinic24. For a slide to be considered positive, at least five asexual stage parasites had to be seen. These slides were later confirmed by others in a laboratory and results returned to the clinic. If a slide was read as negative in the clinic and later found to be positive, the volunteer was treated. There were no slides read as positive in the clinic that were negative on confirmation. Unless otherwise stated, parasitemia refers only to P. falciparum, and not P. malariae or P. ovale. The tabulation of blood slides for the purpose of vaccine efficacy was begun 14 days after the day of completion of doxycycline administration (not with the day after the completion of immunization), to avoid including any recrudescent parasites. Thus, observation periods 1 and 2 began 14 days after each of the first two vaccines were given (Figure 1 and Figure 4a,b) , and observation period 3 began 60 days after the third vaccine was given (study day 230, Figure 1 and Figure 4~ ). Serum doxycycline was assayed by reverse phase high-pressure liquid chromatography on samples from the 9th, 10th or 1 lth day of prophylaxis . Urine was collected every 4 weeks, frozen and analyzed for aminoquinolines26, 7.
Clinical hematology, urinalysis and chemistry tests were performed at initial screening, monthly for 12 months and when clinically indicated.
Humoral and cellular immunology
Levels of anti-P. falciparum circumsporozoite (CS) antibody were determined by enzyme-linked immunosorbent assay (ELISA)28 with capture antigen R32LR. Standard sera containing 9.8 pug of IgG antibody per ml, specific to R32 from a previously vaccinated volunteer3,29 and test sera, gave co-parallel curves of absorbance vs concentration when tested against R32LR3'. Positive was defined as the mean plus 3 S.D. of nonimmune sera without exposure to malaria. Rise in titer was defined as a level 3 S.D. above the preimmunization level for that individual. Immunofluorescent assay for antibody to sporozoites was performed before the first and after the third vaccination' '.
Lymphocyte proliferation was performed 4-8 days before the first vaccination, 1 month before and immediately before the third vaccination, and 1 month, 2 months and 6 months after the third vaccination7.
Entomological background and measurement
The Kenya, 86 .6% of naturally infected An. gambiae transmitted, into sucrose or blood, a geometric mean of 3.84 sporozoites (range l-34), about 3% of the total sporozoites in salivary glands13. In contrast, laboratory reared An. gambiae contained 808-13905 sporozoites, and 44.1% of infected laboratory An. gambiae transmitted a geometric mean of 4.5 (maximum 369) sporozoites in vitro, with which sporozoite loads were not a predictor of the number of sporozoites ejected14. The entomological inoculation rate (EIR), calculated as the monthly man biting rate times the sporozoite rate"', or the average number of potentially infective Anopheles bites in a period of time, was during a previous study in Saradidi, 237 per year inside houses, and 190 per year outside houses32. The calculated time to inoculation exposure, to experience one potentially infective bite, is l/EIR, for Saradidi, inside houses, 1.5 nights32.
Six mornings per week, a 0.5 h collection of indoor resting mosquitoes was made by volunteers in the houses. One morning per week, experienced entomology workers made the collections.
Mosquitoes were identified to species, and examined for the presence of blood. Four days per week, Anopheles were killed, desiccated and mosquito thoraces were tested later for P. falciparum antigen, by ELISA3'. Three days per week, mos3guitoes salivary glands were dissected for sporozoites , which were tested by ELISA for P. falciparum antigen3' and mosquito blood meals were typed for blood groups A, B and 04'. Group 0 blood cells were detected by agglutination in the presence of lectin H (American Dade, Miami, FL). Mosquitoes were determined to have fed on a volunteer when the blood type of the blood meal was the same as the blood type of the volunteer, in those pairs of volunteers with differing blood types. Blood meal host origin was determined by ELISA for human or cow immunoglobulin4'. In a previous study, of A. gambiae s.1. and A. funestus collected in houses in Saradidi, 100% of blood meals were human or cow 4' At the conclusion of the obser-. vation period (16 May 1991) 119 pyrethrum-spray-catch collections39 were made in volunteer's houses, immediately following collections by volunteers. These supplemental collections were done to derive an estimate of the Vaccine 1996 Volume 14 Number 8 819 (Giblett, 1991) ;.. 7 15 39% 18% 10 18 26% 47% 33 17 22% 43% 50% 17% (Giblett, (Giblett, 1991) No vector control methods were exercised in the area during the present vaccine study.
Statistical analysis
Efficacy was calculated using the formula I=1 -(1,/1,), where &incidence of symptomatic parasitemia, I,=incidence in the vaccine group, and IrEincidence in the control group. Analysis of variation, x2, correlation coefficient, Fisher's exact test, Kaplan-Meier survival curve with log-rank test, and Student's t-test were used. Statistical calculations were determined with the assistance of StatView 5 12+ TM (Brainpower, Inc., Calabasas, California, 1986) .
RESULTS
Study population and follow up
Age means were similar for the vaccine and control groups ( Table I ). The distribution of sickle trait was similar between the study population and the general population4244 and between the vaccine and control groups. There was no significant difference between the study population and a previously reported distribution of ABO blood types in this population of western Kenya4'. There was no significant difference between vaccine and control groups in distribution of ABO blood types. The prevalence of glucose-6-phosphatase dehydrogenase deficiency was similar between the study population and the general population46. There was no significant difference between vaccine and control groups in prevalence of glucose-6-phosphatase dehydrogenase deficiency (Table 1) . There was no significant difference in volunteer participation between the vaccine and control groups (P>O.25, log rank test). Sixty-nine of 76 volunteers completed the study on day 367. All who left did so for personal reasons: to further their education or seek employment away from the study area.
Safety and adverse reactions
There were no serious adverse reactions to the vaccines or medicines.
Adverse reactions to vaccines were few in number, mild in intensity, and brief in duration in both vaccine and control groups. There were no adverse reactions manifest by the clinical hematology or chemistry tests.
Humoral and cellular immunology
Among those receiving hepatitis vaccine control, 4 of 38 volunteers (10%) had an antibody rise to R32LR 3 S.D. above the arithmetic mean. Among those receiving malaria vaccine, 73% (28 of 38) had an antibody rise to R32 3 S.D. above pre-immunization.
The geometric mean titers for the malaria group increased after each of the vaccinations and fell during the interim (Table 2, Figure 2 ). The geometric mean titers for the control group did not change (Figure 2) .
Among those receiving malaria vaccine there were three patterns of antibody response: no increase, an increase with a drop toward baseline, and a sustained increase.
Those not responding had lower prevaccination levels, and those responding had higher pre-vaccination levels, in agreement with the previous vaccine study showing greater response in those with higher natural levels". In most, the third vaccination did not increase antibody levels beyond that achieved by the first or second vaccinations.
The highest antibody level achieved was 600 pg ml-' . Four of 38 volunteers (10%) receiving malaria vaccine had peak levels in this range. Among controls, some had low levels of antibody, unchanged during the course of the study, and some had higher levels, also unchanged.
There Figure 2 Geometric mean antibody levels for vaccine and control groups. At week 0 there was no significant difference between vaccine and control groups in antibody levels (E0.417, analysis of variance). From 4 to 52 weeks there were significant differences between vaccine and control groups in antibody levels (EO.OOl -0.021, analysis of variance)
immunofluoresence with an increase in antibody by ELISA.
Lymphocyte responses to R32LR were determined in the 11th or 12th month of the study, using fresh, non-cryopreserved, lymphocytes. Results were available on 52 of 76 volunteers (68%), four of whom had positive responses. Two were from the control group, and two from the vaccine group. Among these four volunteers, there was no association between lymphocyte response and post vaccination antibody level. Among all volunteers, there was no association between lymphocyte response and mean change in antibody level after each of the three vaccinations (P=O.964, 0.820. 0.870, ANOVA). The malaria vaccine group did not have an increase in the proportion of volunteers responding to the antigen as a T-lymphocyte epitope, in comparison with the placebo group. There was no correlation between age and stimulation index at end of study (r= -0.055, n=52). T-lymphocyte responses to R32LR were assayed in the 1 week before the first vaccination, using fresh lymphocytes. Technical difficulty prevented completion of the pre-vaccination assay.
Entomology and parasitologic challenge
From May 1990 to May 1991, 10.9% of 18138 desiccated Anopheles females were positive for P. falciparum antigen by ELISA. Of these, A. gambiae comprised 66.5%, A. funestus 32.1% and A. arabiensis 1.4%. 7.75% of 7842 Anopheles females were P. falciparum sporozoite positive, by ELISA, after salivary gland dissections. Therefore, 71.1% of ELISA-positive desiccated Anopheles were potentially infective (i.e. had P. falciparum sporozoites in salivary glands). Plasmodial circumsporozoite antigen exists in anophelene gut, thorax, and salivary glands during the structural development of the incipient sporozoite, before and possibly after, the sporozoite is functionally infective. The presence of antigen alone, in thorax or in salivary gland, by ELISA, does not equate to infectivity. Furthermore, if ~125 sporozoites per mosquito are present, the ELISA may be negative, being below the ELISA test threshold. Visual dissection for the presence of sporozoites was performed and this material tested for P. falciparum circumsporozoite antigen by ELISA.
For desiccated mosquitoes, the total number of P. falciparum ELISA-positive Anopheles caught was 1971. The calculated average of infected Anopheles collected per volunteer was 0.137 per day. The average number of infected Anopheles captured per day among the study houses ranged from 0.02 to 1.18 (Figure 3) . The mean, minimum and maximum number of infected Anopheles per house per day varied for each of the three observation periods (Table 3) .
Of 18 138 mosquitoes 63.2% blood fed by visual inspection. Of 4029 blood-fed mosquitoes for which blood was typed, 94.3% matched the blood type of one of the volunteers in the house in which the mosquito was caught, suggesting that ingress of blood fed mosquitoes from the outside was minimal. Twenty-eight of the 38 houses contained volunteers with different blood types.
Vaccine 1996 Volume 14 Number 8 821 There was no significant difference in the distribution of P. falciparum sporozoite-infected mosquitoes per house among the blood types 0, A, B and AB for vaccine (P=O.597) or control (PzO.565, ANOVA). There was no significant difference in the distribution of P. falciparum sporozoite-infected mosquitoes with matching blood type per volunteer among the blood types 0, A, B and AB for vaccine (P=O.384) or control (P=O.381, ANOVA).
Antimalarial pharmacology
Serum doxycycline levels ranged in the vaccine group (n=34) from 0.196 to 2.975 pg ml-' (mean f 1 S.D. =0.797 f 0.555 ,ug ml-'), and in the control group (n=35) from 0.145 to 2.686 (mean& 1 S.D.= 0.795 f 0.606 ,ug ml-'), between expected published peak (5 pug ml -') and trough (1 pug ml -') levels47. There
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Vaccine 1996 Volume 14 Number 8 were no positive blood slides during the 14 days following the last dose of doxycycline, the expected prepatent period, had an infective bite been received on the first day following cessation of doxycycline. Fifteen of 78 volunteers, each on only one occasion, had a positive urine test for aminoquinoline, indicating compliance (1.6% of a possible 912 occasions) in taking only those medicines prescribed in the clinic, not chloroquine or amodiaquine available commercially.
Clinical and parasitological outcome
During the three postvaccination observation periods, the number of volunteers who developed symptomatic malaria in the vaccine group and control groups were comparable, and there were no significant differences by x2 analysis (Table 4 ). The number of occurrences of symptomatic malaria during each of the three postvaccination observation periods in the vaccine and control groups were comparable, and there were no significant differences by paired t-test (Table 4) . Efficacy was calculated according to the formula I=1 -(I,/ I,)=1 -(31/38)=0.09=9% . The mean number of fever occurrences from any cause, defined as a temperature 3 S.D. above the mean, was 1.3 (range O-5, n=38) for the vaccine group and 1.7 (range O-5, n=36) for the control group. There was no significant difference between the two groups of paired volunteers in the number of fever occurrences (paired 2-tailed r-test, t= -1.247, dj=35, P=O.2208).
None of the volunteers died during the study. None of the volunteers had severe malaria (defined as a positive blood slide for malaria with seizure, loss of consciousness, or hypotension (blood pressure ~80 systolic), cerebral malaria (defined as a positive blood slide with sustained coma)), a seizure, loss of consciousness, or change in mental status.
All volunteers had at least 1 positive blood slide for P. falciparum during each of the three observation periods after each of the three vaccinations, except 1 vaccine and 1 control in the first observation period (Figure da Figure 4 Kaplan-Meier actuarial curves. The tabulation of blood slides for the purpose of vaccine efficacy was begun 14 days after the day of completion of doxycycline administration (not with the day after the completion of immunization), to avoid including any recrudescent parasites. Thus, observation periods 1 and 2 began 14 days after each of the first two vaccines were given (study days 14 and 70, see Fig. 1 ). Observation period 3 began 14+28=42 days after the third vaccine was given (study day 230, see the second vaccination. The highest P. falciparum parasitemia in any volunteer was 63054 mm -3. Survival curves for the proportion of volunteers free of P. falciparum on blood slide after the first, second and third vaccinations showed no difference between the vaccine and control groups by log rank test (Figure 4a-c) . Blood slide results for the two groups of paired volunteers in the three observation periods are show in Table 5 . There was no significant difference in the mean number of days until the first positive slide (patency), the total number of positive slides, the cumulative number of P. falciparum mm -3 (parasite densities), or mean number of P. falciparum mm -3 on first positive blood slide. Twentyeight (36.8%) of 76 volunteers had P. malariae alone or mixed parasitemia for a total of 61 times. Twenty-two (28.9%) of 76 volunteers had P. ovale alone or mixed parasitemia for a total of 29 times. The prevalences of P. falciparum, P. malariae and P. ovale are shown (Table 6 ).
There was no significant correlation between antibody level at weeks 0, 8, 12, 16, 20, 24, 28, 34, 40, 44 , 48 and 52, or the mean over weeks O-52 or 34-52, or the change in antibody level from weeks O-4, 8-12 or 24-28, and time in days to first positive blood slide, cumulative number of positive blood slides, or cumulative number of parasites mm -3 during the third observation period from weeks 34 to 52. Correlation between mean antibody levels over weeks O-52 and number of days to first positive blood slide was rE0.3.
There was no difference between volunteers with and without T-lymphocyte responses in time to first positive slide, total number of positive slides or cumulative parasitemia.
DISCUSSION
This field study was designed to determine the safety and efficacy of a recombinant alum adjuvanted subunit vaccine which induces antibodies against the repeat region of the P. falciparum circumsporozoite protein, in a malaria-experienced population. This vaccine was safe, with a rate of side-effects comparable to that of recombinant hepatitis B vaccine.
The vaccine induced high levels of antibody in a subpopulation, higher than seen previously in nonimmune or in semi-immune volunteers. In this endemic population, responders to this vaccine had higher preimmunization natural antibody levels than nonresponders, as was observed in a similar population no longer living in a malaria endemic area". Antibody levels of vaccines decreased gradually over 12 months. There was an association between having an increase in antibody by ELISA and immunofluoresence, indicating reaction with native sporozoites, but there remained a subset (10 volunteers) who had antibody by ELISA but not by immunofluoresence.
In volunteers immunized with (NANP)3-tetanus toxoid or recombinant R32tet32, although there was a correlation between level of IgG in protected human volunteers and inhibition of sporozoite invasion of cultured HepG2A-16 hepatoma cells, IgG from protected human volunteers did not block sporozoite invasion of human hepatocytes4'. Sporozoites can develop into hepatic schizonts in the presence of antibody to R3249. High levels of antibodies reacting with sporozoites by immunofluorescence inhibit entry and development of sporozoites in hepatocyte culture by only 82-88% and have been found in the presence of blood stage P. falciparum infection, suggesting that a single antigen vaccine may not be adequate5'. Mouse antibody against the R32 recombinant peptide has a delayed inhibitory effect on development of sporozoites in liver cells49. Repeat epitopes may induce a distracting B-l y" body5', 2.
phocyte production of non-protective antiIn the present study the level of antibody did not correlate with the number of positive slides, time to onset of parasitemia or total burden of parasites.
The vaccine did not increase the small proportion mounting a T-lymphocyte response. The present result is consistent with a report that NANP repeat is a T-lymphocyte epitope on the circumsporozoite protein6, but recognized by only a portion of the population (4 of 52=7.7%), in agreement with previous results from the same area (2 of 28=7.1°h)7. The repeat region is conserved among widely separated regions53. Such conservation may reflect the low frequency of individuals whose T-lymphocytes recognize the repeat. Polymorphisms in T-lymphocyte epitopes lie outside the repeat region 54s5 Although exposure to sporozoites boosts immunity initiated by a sporozoite vaccine in mice56, exposure to natural sporozoites after the third vaccination did not appear to increase the proportion of volunteers with a T-lymphocyte response. P. berghei sporozoites do not prime mouse T-lymphocytes for circumsporozoite epitopes5', which appears to be the case for P. falciparum sporozoites in humans, based on the 7% prevalence of T-lymphocyte response to R32LR in this study. This vaccine did not protect this population against malaria. All volunteers acquired parasitemia. Vaccine and control groups had the same malaria-free survival curves, number of positive slides for malaria, parasite densities. This vaccine had protected 1 of 8 non-immune American vaccinees from sporozoite challenge, using 5 laboratory infected An. stephensi mosquitoes, at least 50% of mosquitoes infected with at least 2+(10-100 sporozoites per gland)", with a correlation between immunofluorescence and antibody by ELISA". With this vaccine there had been no correlation between serum inhibition of sporozoite invasion of hepatoma cells with human protection".
Close follow-up and early treatment may have precluded the development of severe malaria, so a vaccine effect on this could not be determined.
This study provides an indirect comparison of experimentally infected laboratory mosquitoes with natural field exposure. The entomological challenge in numbers of P. falciparum sporozoite-infected mosquitoes per volunteer was 0.194 per day, an average of one infectious bite every 5.2 days. Five laboratory infected mosquitoes at once have been used in laboratory efficacy studies3,4%'0. It may be thought that the malaria challenge is high in western Kenya, and too severe a test for vaccine efficacy. However, in this study, there was a 70-fold range in challenge, 3.5-245 P. falciparum infected mosquitoes collected per house. It was important to conclude that absence of malaria was not due to absence of infected mosquitoes.
The SPf66 vaccine has the sequence CGDELEAETQ NWAAP NANP YSLFQKEKMVLP NANP PANKK NAG (NANP=Asn-Ala-Asn-Pro)58.
Immunization of rabbits with SPf66 induced antibody to (Asn-Ala-AsnPro)40, but not of monkeys nor human volunteers5*. SPf66 has been reported 33.6% effective (95% confidence interval l&845.7%), against a first episode of endemic malaria, with blood slides made every 4-8 weeks, in a semi-immune human population in Colombia59, statistically in agreement with the present study (for asymptomatic parasitemia efficacy was O%, for symptomatic parasitemia efficacy was 9%, statistical power 95% probability of efficacy ~50%). Antibody levels to Asn-Ala-Asn-Pro did not correlate with incidence59. It is not clear to what extent two non-contiguous copies of (Asn-Ala-Asn-Pro) in SPf66 contributed to immunogenicity or efficacy. SPf66 was reported to be 55% effective (95% conficence interval 21-75%) with blood slides made every 4-S weeks, in Venezuela6', also statistically consistent with the present study (for asymptomatic parasitemia efficacy was O%, for symptomatic parasitemia efficacy was 9%, statistical power 95% probability of efficacy ~50%). SPf66 was reported to be 31% effective (95% conficence interval O-52%), with blood slides made only if temperature was 37.5", in Tanzania6', also statistically consistent with the present study (for asymptomatic parasitemia efficacy was O%, for symptomatic parasitemia efficacy was 9%, statistical power 95% probability of efficacy ~50%). In the present study, visits to ascertain symptoms were made every day rather than waiting for patients to present, and blood slides were made every 1 week rather than every 4-8 weeks, and with such frequent active seeking the observation remains that every volunteer of both vaccine and control groups had a parastiemia at least once, and both vaccine and control groups had similar incidences of symptomatic parasitemia.
The SPf66 vaccine was tested in the Gambia and found to have a protective efficacy of 8% (95% confidence interval -18%29%, P=0.50)62, in statistical agreement with the present study showing protective efficacy against symptomatic parasitemia of 9% (statistical power 95% probability of efficacy <50%), and also in statistical agreement with the study in Tanzania showing protective efficacy of 31% (95% conficence interval O-52%)61.
With R32LR, in an immunigenicity study in semiimmune volunteers, with vaccination at 0, 8 and 16 weeks, in Thailand, anti-circumsporozoite antibodies rose significantly, but fe1163. Minimal rainfall precluded natural malaria challenge, leaving the question of vaccine efficacy unresolved in that study62.
Newer candidate vaccines may induce both humoral and cellular immunity, with better adjuvants, presentation and delivery of antigens against multiple parasite stages.
This present study in malaria-endemic semi-immune volunteers was useful for comparison with studies in animals and non-immune volunteers, in the absence of definitive laboratory assays of protective immunity. It showed that high levels of anti-circumsporozoite repeat antibody, induced by this antigen, with this adjuvant, were ineffective in preventing malaria in this endemic population, exposed to a range of intensity of natural challenge.
